Criteria Based Consultation Prescribing Program
CRITERIA FOR DRUG COVERAGE
methylphenidate (Cotempla XR-ODT™)

Non-formulary **methylphenidate (Cotempla XR-ODT™)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of ADHD or ADD

-AND-

1) For patients under age 21:

- Patient has documented intolerance or contraindication to sprinkle formulations and is unable to swallow whole tablets

-OR-

- Patient is already stable on the drug

2) For patients 21 years of age or older NOT currently taking Cotempla XR-ODT™:

- Adequate trial** (7 days) of methylphenidate ER (Metadate CD or Ritalin LA), **unless** allergy to an inactive ingredient

-AND-

- Adequate trial** (7 days) of methylphenidate ER (Concerta) (must have at least partial response), **unless** allergy to an inactive ingredient

3) For patients 21 years of age or older currently taking Cotempla XR-ODT™:

- Adequate trial** (7 days) of methylphenidate ER (Metadate CD or Ritalin LA) (must have at least partial response), **unless** allergy to an inactive ingredient, or currently taking methylphenidate ER (Cotempla XR-ODT) with an antipsychotic or mood stabilizer (lithium or an antiepileptic drug used for mood stabilization)

-AND-

- Adequate trial** (7 days) of methylphenidate ER (Concerta) (must have at least partial response), **unless** allergy to an inactive ingredient, or currently taking methylphenidate ER (Cotempla XR-ODT) with an antipsychotic or mood stabilizer (lithium or an antiepileptic drug used for mood stabilization)

-OR-

- Dose change only: patient meets current criteria and is already taking the drug

** Adequate trial of a long acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.